The table below is a summary of the segment loss, including significant segment expenses (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2025 |
|
|
2024 |
|
|
|
(in thousands) |
|
Program expenses |
|
|
|
|
|
|
Navacaprant (NMRA-140) program |
|
$ |
(93,204 |
) |
|
$ |
(105,442 |
) |
M4 PAM programs |
|
|
(12,277 |
) |
|
|
(11,041 |
) |
NMRA-511 program |
|
|
(8,097 |
) |
|
|
(7,236 |
) |
Preclinical programs |
|
|
(10,987 |
) |
|
|
(5,776 |
) |
Research and development personnel-related costs |
|
|
(36,052 |
) |
|
|
(47,036 |
) |
General and administrative expense |
|
|
(60,091 |
) |
|
|
(62,537 |
) |
Acquired in-process research and development |
|
|
(5,000 |
) |
|
|
— |
|
Interest income |
|
|
8,344 |
|
|
|
19,933 |
|
Interest expense |
|
|
(3,219 |
) |
|
|
— |
|
Other segment items(1) |
|
|
(16,345 |
) |
|
|
(24,652 |
) |
Net loss |
|
$ |
(236,928 |
) |
|
$ |
(243,787 |
) |
(1) Includes other research and development costs, provision for income taxes, and other income (expense)
|